Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jazz Tunes Up For Business Development

This article was originally published in The Pink Sheet Daily

Executive Summary

With a highly competitive effective tax rate, half a billion dollars in cash, and access to attractively priced capital, specialty pharma Jazz, itself the subject of takeover rumors, has stepped up its ongoing hunt for late-stage assets.

Advertisement

Related Content

Jazz’s $1 Billion Buyout Of Gentium Adds To European Hematology Franchise
Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid
Jazz Cools On Women’s Health, Sells Unit To Meda
Jazz Enters Oncology Market With EUSA Acquisition
Jazz Pharmaceuticals Improvises Its Way To A Turnaround

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS076202

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel